Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults

Highlights • Pneumococcal serotypes causing serious adult outcomes included in both PPSV23 & PCV13. • Serotype 6A linked with elevated risk in three studies. • Nine PPSV23-unique types linked with elevated risk in 14 studies. • Serotypes 11A and 9N repeatedly caused elevated case-fatality rate i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2014-05, Vol.32 (21), p.2399-2405
Hauptverfasser:	Grabenstein, John D., RPh, PhD, Musey, Luwy K., MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Allergy and Immunology Applied microbiology Bacterial diseases Bacteriology Biological and medical sciences Case-fatality rate Clinical outcomes Fundamental and applied biological sciences. Psychology Human bacterial diseases Humans Infectious diseases Medical sciences Meningitis Microbiology Miscellaneous Mortality Pneumococcal Infections - epidemiology Pneumococcal Infections - microbiology Pneumococcal Infections - prevention & control Pneumococcal vaccine Pneumococcal Vaccines - administration & dosage Pneumonia Quality-Adjusted Life Years Risk Factors Serotyping Staphylococcal infections, streptococcal infections, pneumococcal infections Streptococcus pneumoniae Streptococcus pneumoniae - classification Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Conjugate - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Pneumococcal serotypes causing serious adult outcomes included in both PPSV23 & PCV13. • Serotype 6A linked with elevated risk in three studies. • Nine PPSV23-unique types linked with elevated risk in 14 studies. • Serotypes 11A and 9N repeatedly caused elevated case-fatality rate in adults. • Serotypes 10A and 15B repeatedly caused elevated meningitis risk in adults.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2014.02.096